ProQuant™, a world-leading proteomics platform delivering unparalleled precision
ProQuant™, a world-leading proteomics platform delivering unparalleled precision
Welcome to ProQuant™
ProQuant™ is a world-leading proprietary platform for performing LC-MS/MS bottom-up proteomics on a wide range of biological samples, delivering precision unachievable with any other technology. The step-change in quantitative performance unleashes the promised power of proteomics, and the platform is now being provided by RxCelerate with the power to speed up and de-risk multiple phases of the drug development pipeline.
CUSTOM PROJECTS
We will apply our proprietary platform and expertise to design and provide custom proteomics projects designed for just one thing – to provide the solution to your questions.
NO BIAS
All of our proprietary methods and custom algorithms are unsupervised, meaning no bias can be introduced into your data.
PART OF A BIGGER FAMILY
RxCelerate are able to provide fully integrated programmes for drug discovery from small molecule or antibody design right through to preclinical studies and beyond.
Our Services
ProQuant™ has many different applications including:
Target identification
Biomarker identification
Biologics development and CMC
Label characterisation
Chemoproteomics
PTM characterisation
Our Platform
ProQuant™ is a bottom-up proteomics platform, performing high resolution LC-MS/MS analysis of proteins. We have evaluated and optimised each stage of the process to be as quantitative as possible. This has resulted in a proprietary proteomics process that has exceptional quantitative reproducibility. In tests we have replicate CVs of <20% for over 80% of the proteins quantified in a complex biological sample – with this replicate reproducibility including the entire protocol: sample preparation, digestion, LC-MS/MS and data processing. This exceptional level of performance not only improves outcomes for traditional applications but expands the range of applications in which it can be used.
About RxCelerate
ProQuant™ is a new offering introduced after acquisition of the proteomics team from Methuselah Health in 2022. RxCelerate was founded in 2013 with a vision to provide a bespoke high-quality outsourced drug discovery and development platform. Originally focused on delivering preclinical and in vitro biology services, during the last nine years we have expanded our in-house capabilities to include chemistry, in silico design, systems biology and project and programme management.
Got an Enquiry?
Keep up to date
Find out the latest news and updates from RxCelerate, RxBiologics and ProsaRx by following us on social media:
Get in touch
Call Us 01223 839557
Email Us [email protected]
Visit Us
RxCelerate Ltd
Dorothy Hodgkin Building,
Babraham Research Campus,
Babraham, Cambridge CB22 3FH
